Abstract
Objective
Amlodipine is a calcium antagonist of the dihydropyridine class. This study was performed to examine the single and multiple dose pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis and to measure the index of accumulation during multiple dosage. An additional objective was to examine the dialysability of amlodipine by measuring its appearance in dialysate.
Methods
Seventeen hypertensive out-patients on haemodialysis were enrolled in this prospective, open, non-comparative phase-IV study. Fifteen patients completed the study. In the first part of the study, the patients were given a single oral 5-mg dose of amlodipine and blood samples taken 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 72 and 144 h later. After a 4-week wash-out period, the patients were given a daily 5-mg oral dose of amlodipine for 30 days. The trough levels of amlodipine were measured on days 8, 15, 22 and 29. On day 30, the total time course of amlodipine concentrations in plasma was measured, as in the first part of the study. In addition, on day 15, the concentrations of amlodipine in dialysate were measured at the same time as in blood. Blood pressure and heart rate were measured and adverse events monitored. Pharmacokinetic parameters [Cmax, tmax, kel and AUC(0–24)] were calculated for the single dose and for the dose on day 30 and the accumulation index calculated on the basis of AUC(0–24) and Cmax.
Results
The mean values of the single-dose pharmacokinetic parameters were as follows: Cmax 3.83 µg l−1, tmax 5.01, AUC(0–24) 59.90 µg l−1 h, kel 0.0177 h−1. The mean accumulation index on the basis of AUC(0–24) was calculated as 3.70. Very low levels of amlodipine were detectable in dialysate fluid. The most frequently reported adverse events were hypertension, hypotension and muscle cramps.
Conclusion
There are only minor differences in the pharmacokinetics of amlodipine between healthy subjects and hypertensive patients on haemodialysis. Comparison with literature values for healthy volunteers suggests that amlodipine is rapidly and extensively absorbed in the patient group. Amlodipine is essentially not dialysable. These findings do not indicate a need for dose adjustment in renal failure patients on haemodialysis.
Similar content being viewed by others
References
Haria M, Wagstaff AJ (1995) Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 50:560–586
Meredith PA, Elliott HL (1992) Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 22:22–31
Laher MS, Kelly JG, Doyle JG, Carmody M, Donohoe JF, Greb H, Volz M (1988) Pharmacokinetics of amlodipine in renal impairment. J Cardiovasc Pharmacol 12[Suppl 7]:S60–S63
Beresford AP, Macrae PV, Stopher DA, Wood BA (1987) Analysis of amlodipine in human plasma by gas chromatography. J Chromatogr 420:178–183
Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S, Friedman HL (2000) Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol 50:455–463
Abernethy DR (1994) An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol 73:10A–17A
Josefsson M, Zackrisson A-L, Ahlner J (1996) Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 51:189–193
Elliott HL, Meredith PA, Reid JL, Faulkner JK (1988) A comparison of the disposition of single oral doses of amlodipine in young and elderly patients. J Cardiovas Pharmacol 12[Suppl 7]: S64–S66
Elliott HL, Green ST, Vincent J, Meredith PA (1992) An assessment of the pharmacokinetics and pharmacodynamics of single doses of amlodipine in elderly normotensives. Pharmacol Res 26:33–39
Acknowledgements
This study was sponsored by Pfizer, Germany. This study complies with the current German laws.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kungys, G., Naujoks, H. & Wanner, C. Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. Eur J Clin Pharmacol 59, 291–295 (2003). https://doi.org/10.1007/s00228-003-0620-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0620-4